2 Minute Medicine Rewind February 17 – February 23, 2014
Image: PD In this section, we will highlight the key high-impact studies, updates, and analyses published in medicine during the ...
Tag: Alzheimer’s disease
Daily citalopram associated with decreased agitation in Alzheimer’s disease
Image: PD 1. Daily treatment with citalopram in patients with probable Alzheimer disease was associated with decreased agitation compared to ...
Donepezil and vitamin E in Alzheimer’s disease [Classics Series]
Image: PD 1. High-dose vitamin E supplementation does not slow down progression to Alzheimer’s disease 2. Donepezil, a cholinesterase inhibitor, ...
2 Minute Medicine Rewind Jan 20 – Jan 26, 2014
Image: PD In this section, we will highlight the key high-impact studies, updates, and analyses published in medicine during the ...
Bapineuzumab does not improve clinical outcomes in Alzheimer’s disease
Image: PD 1. Bapineuzumab, a humanized anti-Aβ monoclonal antibody, did not improve clinical outcomes in patients with mild-to-moderate Alzheimer’s disease. ...
Solanezumab does not improve cognition or functioning in Alzheimer’s disease [EXPEDITION Trials]
Image: PD 1. Solanezumab did not improve cognition or functional ability in mild-to-moderate Alzheimer’s disease at week 80. 2. Solanezumab ...
2 Minute Medicine Rewind December 31-January 6, 2013
Image: PD/Tau Protein Alzheimer Disease In this section, we will highlight the key high-impact studies, updates, and analyses published in ...
Vitamin E associated with slower functional decline in Alzheimer disease [TEAM-AD Trial]
Image: PD 1. Vitamin E supplementation was associated with decrease in the rate of loss in activities of daily living ...
PET scans accurately identify amyloid deposition after traumatic brain injury
Image: PD 1. Amyloid plaques, similar to those found in Alzheimer’s disease were found in traumatic brain injury (TBI) victims. ...
Phase 3 trial fails to demonstrate benefit of semagacestat in Alzheimer’s disease
Image: PD 1. Use of semagacestat was associated with dose-relevant clinical worsening. 2. There were also renal and immunologic effects ...
